Skip to main content
AVBP logo

ArriVent BioPharma, Inc.

AVBPNASDAQHealthcareBiotechnology

$16.66Today:- (-)1Y −13.94%

As of Oct 16, 2026 close

Market cap
$799.32M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$11.36$35.83
Volume (live)
-
Avg. volume (3M)
1.62M

ArriVent BioPharma (AVBP) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), ArriVent BioPharma used $160.59M of cash in operating activities. Free cash flow was −$160.59M.

ArriVent BioPharma Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ArriVent BioPharma, Inc. (AVBP) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-166.31-80.49-69.33-36.91-51.61
Depreciation & Amortization-3.030.000.000.000.00
Stock Based Compensation12.523.210.900.420.07
Change in Working Capital-3.777.0712.60-7.15-3.94
Change in Accounts Payable2.14-0.751.382.800.29
Change in Other Working Capital-12.581.4411.22-9.95-4.23
Other Operating Activities-3.030.000.000.0042.89
Net Cash from Operating Activities-160.59-70.21-55.84-43.63-12.59
Investing Activities
Purchases of Investments-272.93-194.16-25.000.000.00
Sales/Maturities of Investments201.711.7025.000.000.00
Other Investing Activities0.000.000.000.00-40.00
Net Cash from Investing Activities-71.23-192.470.000.00-40.00
Financing Activities
Common Stock Issued203.13186.580.350.0089.87
Other Financing Activities-0.070.6342.51169.720.00
Net Cash from Financing Activities203.06186.5842.86169.7289.87
Summary
Net Change in Cash-28.75-76.10-12.98126.0937.28
Cash at Beginning of Period74.29150.39163.3737.280.00
Cash at End of Period45.5474.29150.39163.3737.28
Free Cash Flow-160.59-70.21-55.84-43.63-12.59

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ArriVent BioPharma Cash Flow

What is ArriVent BioPharma's free cash flow?

ArriVent BioPharma had negative free cash flow of $160.59M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does ArriVent BioPharma pay dividends or buy back shares?

ArriVent BioPharma's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition